Go Industries Inc. is bringing something new to the table with its latest product. They’ve launched the Commercial Grade Winch Grille Guard, which is a fresh advancement for truck protection. This grille guard is modular, which means truck lovers can start with the basic setup and then add a winch carrier and brush guards if they need them later. Built tough, it uses 5/16 laser cut steel uprights and 2.5″ 16 gauge steel cross tubes to really shield vehicles.
The CEO of Go Industries shared his enthusiasm: “We’re excited to introduce this new product to our lineup. The Commercial Grade Winch Grille Guard showcases our commitment to quality and innovation in the design and protection of trucks. Our products are crafted to meet the needs of both everyday drivers and those who demand more from their vehicles, especially in challenging environments.”
Installing the new winch grille guard is designed to be straightforward. It comes with custom, heavy-duty brackets that make sure it is super strong and easy to set up. This focus reflects Go Industries’ goal to make products that are practical and user-friendly. For extra personalization, vehicle owners can pick optional brush guards that protect headlights from debris while also boosting the vehicle’s look.
This product isn’t just for one kind of vehicle. It can be customized to fit different truck models and setups. For example, there’s a specific ford expedition winch grille guard designed to perfectly fit and protect the popular model. This high level of customization is crucial, especially for those who take their vehicles off-road where tough conditions demand reliable gear.
Go Industries also offers add-ons like 9.5 or 16.5 winch carriers, greatly enhancing what the vehicle can do. There’s a three-year warranty included, covering materials, workmanship, and finish, which gives customers peace of mind about the product’s durability. Highlighting American craftsmanship, these parts are made in the USA, underscoring the company’s commitment to quality and supporting local manufacturing.
Besides, Go Industries doesn’t just serve regular drivers. They also produce accessories for law enforcement vehicles, aiming to boost both functionality and safety. Their custom manufacturing service is available for clients with unique needs, showing Go Industries’ ability to adapt to various customer demands.
The lead of Product Development at Go Industries added, “Our aim is always to deliver products that meet the highest standards of performance and dependability. With the introduction of the winch grille guard, we are reinforcing our reputation as a leader in truck accessories, providing solutions that our customers can rely on regardless of their vehicle’s purpose.”
For those who want to know more, Go Industries’ website has a full product catalog, installation guides, product details, and videos. This kind of information helps customers make informed choices before buying and setting up their new gear.
Adapting to the changing financial world, Go Industries not only accepts traditional credit card payments but also cryptocurrency. This demonstrates their readiness to adopt modern payment methods, widening their customer reach and showing a blend of technology and product excellence.
The launch of the Commercial Grade Winch Grille Guard represents Go Industries’ strong focus on innovation and customer satisfaction. By constantly improving product technology and their manufacturing process, Go Industries holds its ground as a trusted name in the truck accessories field. Interested buyers can check out their official website for more details or to place an order, making this exciting new addition, including the ford expedition winch grille guard, available to drivers across different terrains and vehicle types.
Cortes Law Firm, located in Oklahoma City, has announced a fresh initiative to help families handle the probate process more smoothly. Known for its expertise in probate, estate planning, and trust administration, the firm is dedicated to educating people about these legal processes in Oklahoma. Through the Cortes Law Firm Press, they keep the community informed with regular updates and insights.
Stephen L. Cortes, the firm’s lead attorney with over two decades of legal experience, stresses how important clear guidance is during the often bewildering probate process. Understanding local probate laws is a key part of how the firm assists families efficiently. “Our goal is to make the probate process easier for families in Oklahoma City,” Cortes said. “We want to support them every step of the way.”
The Cortes Law Firm offers more than just legal services. It is committed to a broader educational mission, aiming to enlighten Oklahoma City residents about the importance of proper estate planning and how Oklahoma probate laws affect them. This mission is vital because estate administration can be complicated within the local legal system. Many families find the probate process overwhelming, due to the legal language and complexities that can create real challenges without the right guidance.
Cortes Law Firm now provides detailed insights into Oklahoma County probate court procedures and state-related laws that affect the execution of wills, trusts, and other important documents. Their approach includes preparing clients thoroughly by creating necessary legal documents and ensuring they are executed correctly. This proactive method aims to reduce disputes among heirs and prevent estates from being mishandled, which could lead to serious legal and financial issues.
Steve Cortes highlighted the firm’s community-centered approach by saying, “We believe in laying a strong foundation. By connecting with our clients and the Oklahoma City community, we aim to build the trust that enables us to work together effectively, ensuring their legacies are preserved.”
Cortes Law Firm Oklahoma City‘s dedication to local residents remains strong, focusing on personalized attention and tailored legal solutions. As they expand their outreach and educational efforts, the firm continues to be a leading authority in probate and estate planning in Oklahoma City. The firm’s published guides and resources are readily accessible, providing in-depth information on topics such as inheritance tax, probate litigation, and choosing executors.
People who want to learn more about these areas can access resources directly on the firm’s website. This is part of a broader digital effort to ensure the community has access to valuable information. The educational materials are enriched with regular updates and informative videos covering both basic and current issues related to probate law and estate planning.
Situated in central Oklahoma City, Cortes Law Firm has established itself as a key player in the local legal field and a supportive partner for clients undertaking the tasks of probate and estate planning. Detailed information about their services and educational resources can be found by visiting their website. The firm’s comprehensive method focuses on carefully titling assets, setting up revocable living trusts, and preparing healthcare power of attorney documents, among other critical services.
For those looking for expert advice and dependable legal support, Cortes Law Firm offers free consultations to answer pressing questions and provide strategic guidance. Prospective clients and others interested in learning more about available services are encouraged to reach out.
Residents of Oklahoma City in need of guidance on probate or estate planning can contact Cortes Law Firm at (405) 213-0856 or visit their website for more information. The Cortes Law Firm Press ensures that the firm’s ongoing efforts to provide detailed legal resources are highlighted, reinforcing its reputation as a trusted source for estate administration and legal advice in Oklahoma.
Safety First Training Ltd. has been a leader in safety education for more than 30 years. They focus on workplace safety, especially through their Forklift Operator Certification Program. This program is available in Toronto, Mississauga, the Greater Toronto Area, and all across Ontario. It is tailored to equip workers with the skills needed to operate forklifts safely while meeting Canadian safety standards. Courses from Safety First Training Toronto are vital for companies looking to improve their safety measures and follow necessary regulatory requirements, which are key for both efficiency and worker well-being.
The program provided by Safety First Training combines both classroom learning and hands-on practice. This ensures that forklift operators not only know the technical details but also understand safety procedures. The course covers equipment inspections, effective load handling, identifying and reducing workplace hazards, and following safe operational strategies. These elements help create a safer work environment, reduce accidents, and enable workers to do their jobs well.
Participants must pass a series of written and practical tests to prove their understanding and skill in operating forklifts safely. Those who pass earn a certification according to CSA Standard B335-15. This certification is a recognized credential for forklift operator qualifications and matches both provincial and federal standards. Its recognition highlights the program’s alignment with national safety rules, contributing to nationwide safety compliance.
“Forklifts are vital to many industries, but without proper training, they can pose serious safety risks,” said Kevin Mork, CEO of Safety First Training Ltd. “Our program gives operators the confidence and competence to work safely, while helping organizations maintain compliance and reduce workplace incidents.”
The training is designed for a wide range of participants, such as newcomers to forklift operations, experienced workers needing recertification, and industry employees in warehousing, manufacturing, construction, and logistics. The program covers various types of forklifts, and experienced instructors adjust the course to suit different categories, ensuring a comprehensive understanding and skills development. For companies interested in self-sufficiency, Safety First Training also offers a Train the Trainer program which allows companies to develop their in-house safety experts.
Safety First Training Toronto is dedicated to offering flexible training options. They provide scheduling choices and on-site training to allow companies to incorporate certification into their operations without significant downtime. This flexibility supports companies in keeping up with their work demands while boosting their workforce’s safety skills.
The process for enrolling in Safety First Forklift Training Toronto‘s certification program is simple. Companies can tailor the training according to their needs, considering factors such as group size, experience level, or location. This adaptability and commitment to quality training have built client trust across various industries. By addressing specific business needs, Safety First Training solidifies its role as a dependable partner in workplace safety.
To learn more about the Forklift Operator Certification Program and see how Safety First Training can help achieve safety aims across different fields, visit the company’s website. Businesses can find out more about the program’s benefits and how it helps maintain a culture of safety within organizations.
WELLESLEY, MA / ACCESS Newswire / August 12, 2025 / MDaudit, an award-winning cloud-based continuous risk monitoring platform for RCM that enables the nation’s premier healthcare organizations to minimize billing risks and maximize revenues, has finalized its acquisition of Streamline Health Solutions, Inc., a leading provider of solutions that enable healthcare providers to improve financial performance. The addition of Streamline’s pre-bill integrity solutions to its robust billing compliance and revenue integrity platform positions MDaudit to bridge crucial RCM gaps, thereby mitigating billing compliance risks and strengthening and streamlining the revenue cycle.
First announced in May, the acquisition brings together two healthcare RCM powerhouses supporting healthcare organizations with a combined net patient revenue of more than $300 billion. The companies’ shared belief in centering customer satisfaction while leveraging the latest technologies converges into a powerful platform capable of meeting head-on the revenue cycle realities confronting organizations in today’s complex healthcare environment.
“Navigating the unrelenting financial and operational pressures of the current revenue cycle landscape requires a strategic approach to revenue cycle management, one in which real-time data, AI, analytics, and automation provide an uninterrupted view across the revenue cycle continuum,” says Ritesh Ramesh, CEO of MDaudit. “This acquisition allows us to provide healthcare organizations with the data- and AI-driven solutions they need to implement an effective, resilient, and adaptive RCM strategy.”
The award-winning MDaudit platform streamlines healthcare revenue integrity using augmented intelligence. It rapidly analyzes billions of rows of data, monitors coding, billing, and payment processes, and uses AI-powered tools to democratize insights and automate workflows. Benchmarking helps identify charge capture and denial issues, while retrospective audits drive staff education to prevent errors.
Streamline Health’s RCM solutions empower healthcare providers to manage and optimize their revenue streams more efficiently. Its suite of comprehensive solutions focuses on pre-bill charge and coding integrity, ensuring that all charges and coding are accurate before billing and payment. By preventing lost revenue and minimizing denials, Streamline Health enables providers to secure the reimbursement they deserve.
Cain Brothers, a division of KeyBanc Capital Markets, acted as exclusive financial advisor to Streamline, which is now a private company and wholly owned subsidiary of MDaudit. Troutman Pepper Locke LLP served as Streamline Health’s legal counsel. Goodwin Proctor, LLP served as legal counsel to MDaudit.
About MDaudit
MDaudit is a leading healthcare technology provider that partners with the nation’s premier healthcare systems to reduce compliance risk, improve efficiency, retain revenue, and enhance communication between cross-functional teams. Bringing solutions to an industry in transformation, MDaudit enables organizations to minimize billing risks and maximize revenue with an AI-powered, integrated, cloud-based platform that leverages the power of collaboration between people and sophisticated technology to keep humans at the forefront of decision-making while driving sustainable change. To learn more, visit www.mdaudit.com/.
About Streamline Health
Streamline Health Solutions, Inc. enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Strategic acquisition expands capabilities in financial incentives and behavioral engagement, further strengthening Clutch’s growing healthcare footprint
AMBLER, PENNSYLVANIA / ACCESS Newswire / August 12, 2025 / Clutch, the leading AI-powered engagement platform serving both commerce and healthcare verticals, today announced its acquisition of Reciprocity Health, a healthcare technology company known for its behavioral science-driven approach to financial incentives and patient engagement.
The acquisition marks a significant expansion of Clutch Health, Clutch’s dedicated healthcare business line. By integrating Reciprocity Health’s specialized technology and experienced healthcare team, Clutch Health is poised to scale faster, serve broader use cases, and deliver even more impactful outcomes across the healthcare ecosystem.
“Clutch Health has been growing rapidly, and the addition of Reciprocity accelerates everything; capabilities, talent, and strategic reach,” said Craig Hauben, CEO of Clutch. “We’re combining the science and discipline of healthcare engagement with the consumer-grade technology Clutch is known for. It’s a natural evolution of the platform.”
A Platform Built for Behavioral Impact
This acquisition unites two mission-aligned organizations:
Reciprocity Health’s TheraPay® platform leveraging gamified, incentive-based models to drive plan adherence and patient/member action
Clutch Health’s personalized engagement engine, designed to deliver 1:1 communication and behavioral nudges at scale
Together, Clutch Health will offer enhanced capabilities for healthcare organizations, payers, providers, health plans, cost management and VBC entities to engage consumers more intelligently, efficiently, and measurably.
“With market healthcare opportunities rapidly expanding and a focus towards enhanced consumerism and patient/provider engagement through care journeys,” said Jim Mayhall, CEO of Reciprocity Health. “joining Clutch furthers our mission in empowering patients with customized incentives to enhance adherence, improve outcomes, and reduce costs”
Reciprocity Health was born from the vision of Co-Founders Matt Swanson and Jon Silvon in applying innovative retail behavioral science technology to improve outcomes in complex care journeys for members in vulnerable populations. This vision has broadened to deliver commercially scalable solutions to help activate, empower, and engage members in a variety of healthcare settings.
“This next phase is about more than scaling technology – it’s about combining Reciprocity’s clinical, decision science expertise with Clutch’s world-class AI and data science to redefine how healthcare engagement works,” said Matt Swanson, Co-Founder of Reciprocity Health. “We’re operating in a rapidly evolving market that demands greater precision in patient activation and, together with Clutch, we’re bringing the full power of behavioral science and dynamic incentives to the center of value-based care.”
No Shift Away from Commerce, Just Expanding the Vision
Clutch remains committed to its Commerce line of business supporting leading brands in retail, grocery, restaurants, and consumer services. This acquisition simply reflects Clutch’s multi-sector strategy, where the same core technology powers high-performance engagement across both consumer and healthcare domains.
Under the Clutch umbrella:
Clutch Commerce continues to grow with leading commerce clients
Clutch Health expands its reach, capabilities, and delivery model now strengthened by the Reciprocity Health team and technology
Expanded Capabilities for a Growing Market
With this acquisition, Clutch Health now offers:
Advanced Financial Incentive Management: Deploy secure, gamified incentives tied to plan and program milestones
Hyper-Personalized Outreach: Use AI and behavioral data to drive targeted, outcome-based messaging
Integrated Behavioral Science: Build durable engagement models that improve outcomes and reduce churn
The combined team is already delivering results across existing client portfolios and is poised for rapid expansion through the remainder of 2025 and beyond.
About Clutch
Clutch is an AI-powered Retention, Loyalty, and Engagement Platform that helps businesses in Commerce and Healthcare build stronger relationships with their customers, patients, and members. Through personalized, data-driven communication, automation, and incentives, Clutch helps clients drive measurable outcomes in loyalty, retention, and health engagement.
About Reciprocity Health
Reciprocity Health is a healthcare engagement company that uses behavioral science and financial incentives to activate patients and members. Its flagship platform, TheraPay®, delivers personalized nudges, gamified engagement, and real-time rewards to help individuals take action on their care plans and health journeys.
New survey of 600 enterprise leaders reveals growing investment in IT asset management, yet alarming visibility and alignment gaps persist across organizations.
BOULDER, CO / ACCESS Newswire / August 12, 2025 / WanAware, an innovator in intelligent observability, today released a new report titled Closing the ITAM Confidence Gap: 2025 Survey Insights for IT Leaders, uncovering a stark divide in how IT teams and the broader business perceive the value and performance of ITAM systems. While IT managers express growing confidence in their tools, data, and ROI, most other departments remain unconvinced and often left in the dark.
According to the survey of 600 professionals across IT, operations, and general management at multi-location enterprises, 95% of IT leaders say they trust their asset data, and 80% report growing investment in ITAM initiatives. But outside of IT, that confidence quickly erodes. Less than half of analysts feel good about ROI, and only 35% of other managers trust the accuracy of asset data.
“This isn’t just a perception problem, it’s an operational one,” said Jeff Collins, CEO of WanAware. “When confidence in IT asset data drops by half outside the IT department, it creates real risk, wasted spend, and delays that fly under the radar until it’s too late.”
The report highlights how manual effort, fragmented tooling, and poor visibility continue to plague ITAM workflows. Nearly a quarter of IT teams still rely on spreadsheets and email threads to track assets. And even as IT leaders consolidate systems and adapt, the rest of the organization sees little progress. Non-IT respondents report fragmented tools, slow onboarding, and inconsistent data, undermining trust and making collaboration harder across finance, procurement, and compliance.
The gap is more than frustrating, it’s expensive. The survey estimates up to 25% of IT spend is wasted on “ghost assets” including devices and licenses that are no longer in use but remain on the books. These blind spots often fly under the radar, exposing companies to unnecessary tax, security, and compliance risk.
When asked what would improve ITAM most, IT leaders weren’t asking for bells and whistles. They pointed to real-time updates, automated responses to risky assets, and simplified tools that remove the burden of manual tracking. The goal is clear: fewer roadblocks, not more features.
The disconnect also appears to be widening. Half of IT managers say missing assets cause significant disruption, compared to just 9% of their peers in other departments. And while IT teams report improved visibility since shifting to remote work, analysts and ops managers see no such benefit. These perception gaps fuel disengagement, workarounds, and wasted time, ultimately weakening the business case for ITAM investment.
Still, WanAware believes alignment is possible. The report calls on IT leaders to take a more strategic role by proving the value of ITAM in business terms, integrating it with cybersecurity and service management tools, and making data and dashboards accessible to non-technical teams.
“Asset management shouldn’t be a gatekeeping function,” said Collins. “It should be a command center. When asset data is real-time, trusted, and actionable, it becomes the foundation for smart operations, secure systems, and scalable growth.”
WanAware’s own platform is built to solve exactly these issues, eliminating ghost assets with automated discovery, providing a shared real-time view across departments, and triggering policy-based remediation the moment an asset goes missing or risky. That combination of observability and automation is already helping enterprises close the confidence gap and regain control over sprawling, hybrid IT environments.
Download the full 2025 ITAM Confidence Gap survey report here. Organizations can also now capitalize on a free 14-day trial of WanAware AIM to uncover gaps in their own environment and see real-time results: https://engage.wanaware.com/free-trial-sing-up
###
ABOUT WANAWARE:
WanAware is an innovator in intelligent observability, dedicated to solving the most pressing challenges in IT performance, availability, and security monitoring. By leveraging advanced technologies, including AI and machine learning, WanAware delivers actionable insights that empower organizations to achieve operational excellence. For more information, visit www.wanaware.com.
Company plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025
Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Thursday, August 14, 2025, at 8:30 a.m. Eastern to review second-quarter 2025 financials and provide corporate updates.
Participation Instructions for Jaguar Investor Webcast
When: Thursday, August 14, 2025 at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
Participation Instructions for Jaguar’s Virtual Presentation at the Emerging Growth Conference
When: Wednesday, August 20, 2025 from 2:55 – 3:05 PM Eastern Time
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that Jaguar will file its 10-Q on August 14, 2025 for the quarter ended June 30, 2025, the expectation that Jaguar will hold an investor webcast on August 14, 2025, and Jaguar’s expectation that Jaguar management will present at the August 2025 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Now Offering Veterinary Hemodialysis, Therapeutic Plasma Exchange, and Hemoperfusion
BEND, OR / ACCESS Newswire / August 12, 2025 / The Veterinary Referral Center of Central Oregon (VRCCO) is proud to announce the addition of advanced Extracorporeal Therapies, including Hemodialysis, Therapeutic Plasma Exchange, and Hemoperfusion, to its suite of specialized veterinary services. VRCCO is honored to be among the few facilities in the US to offer these cutting-edge treatments that provide new hope for pets suffering from acute kidney injuries, chronic kidney disease, immune-mediated diseases, and life-threatening toxicities.
Hemodialysis serves as an “artificial kidney” by filtering a pet’s blood to remove harmful substances such as waste, toxins, and excess fluids. While it does not directly heal the kidneys, it provides a vital window of time for recovery, while significantly improving comfort and quality of life for the pet during this critical period. Hemodialysis is most commonly used for acute kidney injuries, severe electrolyte imbalances, fluid overload, and certain toxicities.
Therapeutic Plasma Exchange (TPE) is a procedure designed to remove harmful substances from a pet’s plasma, replacing it with donor plasma. This therapy is particularly effective in managing severe immune-mediated conditions such as immune-mediated hemolytic anemia (IMHA) and myasthenia gravis, as well as certain toxicities. Pets may experience rapid improvement, particularly with immune-mediated diseases that are unresponsive to conventional treatments.
Hemoperfusion involves filtering a pet’s blood through a cartridge containing activated charcoal or similar materials to adsorb toxins. This technique is especially valuable in cases of NSAID overdoses (e.g., ibuprofen, carprofen) or exposure to other harmful substances where no antidote exists. Treatments are generally completed within 2-4 hours, and a single session is often sufficient if administered before organ damage occurs.
VRCCO utilizes the same advanced dialysis machines and materials used in human medicine, ensuring the highest standards of care. Throughout treatments, patients are continuously monitored for vital parameters including blood clotting times, fluid balance, hematocrit, electrolytes, and cardiac health, with personalized attention from their care team. Pet Parents should also be aware of the following while considering these therapies:
Comfort & Compassionate Care: Dialysis treatments are not painful. Pets rest comfortably on soft bedding under the continuous care and observation of VRCCO’s specialized team. Sedation is rarely required.
Patient Size & Suitability: Most companion animals, regardless of size, can be safely treated. VRCCO’s in-house blood bank ensures the availability of transfusions if necessary.
Prognosis & Expectations: Treatment outcomes are highly variable and depend on the severity and cause of the condition. Some pets may require only a few treatments, while others may need ongoing therapy.
Early Intervention is Critical: Starting dialysis before severe complications arise, such as fluid overload or organ dysfunction, dramatically improves the likelihood of a positive outcome.
The Veterinary Referral Center’s board-certified specialists encourage pet parents and referring veterinarians to consult with them to determine whether these therapies are appropriate for individual cases. In many situations, time is a critical factor and early intervention can be life-saving. To learn more about Extracorporeal Therapies or VRCCO’s comprehensive specialty services, please contact the Veterinary Referral Center of Central Oregon at 541-209-6960 or info@vrcvet.com.
RICHARDSON, TX / ACCESS Newswire / August 12, 2025 / Optex Systems Holdings, Inc. (Nasdaq:OPXS), a leading manufacturer of precision optical sighting systems for domestic and worldwide military and commercial applications, announced financial results for the three and nine months ended June 29, 2025.
Danny Schoening, CEO of Optex Systems Holdings, Inc., commented, “We are proud to announce another record-breaking quarter for revenue, a testament to our unwavering commitment to excellence, reliability, and customer support. This milestone reflects not only our strong operational performance but also the momentum we are building across the business.
“In addition to surpassing previous revenue records, we are excited to report several significant new program wins that expand our footprint in both domestic and international markets. These new awards are the result of our consistent delivery of high-quality products and the trust we have earned as a dependable defense manufacturing partner.
“Our factory performance continues to highlight the strength of our team and the efficiency of our processes. As we celebrate this achievement, we remain focused on sustaining this growth trajectory, investing in innovation, and delivering superior value to our customers and shareholders.
“We thank our employees, customers, and investors for their ongoing support in making this success possible.”
Backlog as of June 29, 2025 was $38.3 million, compared to a backlog of $45.6 million as of June 30, 2024, representing a decrease of $7.3 million, or 16.0% from the prior year June period. Subsequent to the period ended June 29, 2025, the Company announced several new awards including a $2.8 million order for the XM30 program, a $10.2 million five-year requirement-type contract award for optical sighting systems, and a $1.6 million order for laser filters, bringing our total backlog to $45.0 million as of August 5, 2025.
For the three months ended June 29, 2025, our total revenue increased by $2.1 million, or 22.6%, compared to the prior year period. For the nine months ended June 29, 2025, our total revenue increased by $5.5 million, or 22.3%, compared to the prior year period. The increase in revenue was primarily driven by higher periscope production levels at the Optex Richardson segment, combined with increased customer demand across both the Optex Richardson and the Applied Optics operating segments.
Consolidated gross profit for the three months ended June 29, 2025 increased by $0.3 million, or 10.0%, compared to the prior year period. Consolidated gross profit for the nine months ended June 29, 2025 increased by $1.5 million, or 21.6%, compared to the prior year period. The increase in the most recent three and nine-month period gross profit was primarily attributable to increased revenue and changes in product mix.
Our operating income for the three months ended June 29, 2025 increased by $0.3 million, or 18.3%, compared to the prior year period. Our operating income for the nine months ended June 29, 2025 increased by $1.5 million, or 43.8%, compared to the prior year period. The increase in operating income was primarily driven by higher revenue and gross profit.
As of June 29, 2025, Optex Systems Holdings had working capital of $19.4 million, as compared to $15.1 million as of September 29, 2024. During the nine months ended June 29, 2025, we generated operating cash of $5.4 million, primarily driven by increased net income, reductions in inventory and increased accounts payable. During the nine months ended June 29, 2025, we paid $1.0 million against the credit facility and purchased capital assets of $0.5 million.
At June 29, 2025, the Company had approximately $4.9 million in cash and no draws against its revolving credit line. As of June 29, 2025, our outstanding accounts receivable balance was $4.1 million to be collected during the fourth quarter of fiscal 2025.
Our key performance measures for the three and nine months ended June 29, 2025 and June 30, 2024 are summarized below.
(Thousands)
Three months ended
Nine months ended
Metric
Jun 29, 2025
Jun 30, 2024
% Change
Jun 29, 2025
Jun 30, 2024
% Change
Revenue
$
11,110
$
9,060
22.6
%
$
30,038
$
24,552
22.3
%
Gross Profit
$
3,168
$
2,881
10.0
%
$
8,658
$
7,122
21.6
%
Gross Margin %
28.5
%
31.8
%
(10.4
)%
28.8
%
29.0
%
(0.7
)%
Operating Income
$
1,911
$
1,615
18.3
%
$
5,065
$
3,523
43.8
%
Net Income
$
1,510
$
1,261
19.7
%
$
4,122
$
2,754
49.7
%
Adjusted EBITDA (non-GAAP)
$
2,125
$
1,837
15.7
%
$
5,698
$
4,224
34.9
%
The table below summarizes our three- and nine-month operating results for the periods ended June 29, 2025 and June 30, 2024, in terms of both the GAAP net income measure and the non-GAAP Adjusted EBITDA measure. We believe that including both measures allows the reader better to evaluate our overall performance.
(Thousands)
Three months ended
Nine months ended
June 29, 2025
June 30, 2024
June 29, 2025
June 30, 2024
Net Income (GAAP)
$
1,510
$
1,261
$
4,122
$
2,754
Add:
Federal Income Tax Expense
401
337
931
737
Depreciation and Amortization
131
132
386
341
Stock Compensation
83
90
247
360
Interest (Income) Expense
–
17
12
32
Adjusted EBITDA – Non GAAP
$
2,125
$
1,837
$
5,698
$
4,224
Adjusted EBITDA has limitations and should not be considered in isolation or a substitute for performance measures calculated under GAAP. This non-GAAP measure excludes certain cash expenses that we are obligated to make. In addition, other companies in our industry may calculate Adjusted EBITDA differently than we do or may not calculate it at all, which limits the usefulness of Adjusted EBITDA as a comparative measure.
Our net income increased by $0.2 million to $1.5 million for the three months ended June 29, 2025, as compared to net income of $1.3 million for the prior year period. Our adjusted EBITDA increased by $0.3 million to $2.1 million for the three months ended June 29, 2025, as compared to adjusted EBITDA of $1.8 million for the prior year period.
Our net income increased by $1.3 million to $4.1 million for the nine months ended June 29, 2025, as compared to net income of $2.8 million for the prior year period. Our adjusted EBITDA increased by $1.5 million to $5.7 million for the nine months ended June 29, 2025, as compared to adjusted EBITDA of $4.2 million for the prior year period.
The increase in net income and adjusted EBITDA for the most recent three and nine-month periods compared to the prior year periods is primarily driven by increased revenue and gross profit.
We currently do not anticipate any significant material risks as a result of the recent tariff uncertainties or China’s stranglehold on rare earths. Our defense products are primarily sourced domestically, but those which are imported are generally not subject to tariff or duties. We produce some commercial optical assemblies with selective components sourced from Taiwan; however, our current customer backlog is covered with existing material in inventory. We anticipate any future orders for these commercial products will be subject to revised pricing inclusive of any potential tariff impact.
Highlights of the Consolidated and Segment Results of Operations have been prepared in accordance with GAAP. These financial highlights do not include all information and disclosures required in the consolidated financial statements and footnotes and should be read in conjunction with our Quarterly Report on Form 10Q for the three and nine months ended June 29, 2025 filed with the SEC on August 12, 2025.
Optex Systems Holdings, Inc. Condensed Consolidated Balance Sheets
(Thousands, except share and per share data)
June 29, 2025
September 29, 2024
(Unaudited)
ASSETS
Cash and Cash Equivalents
$
4,871
$
1,009
Accounts Receivable, Net
4,140
3,764
Inventory, Net
14,514
14,863
Contract Asset
155
219
Prepaid Expenses
469
217
Current Assets
24,149
20,072
Property and Equipment, Net
1,475
1,292
Other Assets
Deferred Tax Asset
852
947
Intangible Assets, Net
845
951
Right-of-use Asset
1,836
2,233
Security Deposits
23
23
Other Assets
3,556
4,154
Total Assets
$
29,180
$
25,518
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts Payable
$
1,778
$
1,177
Credit Facility
–
1,000
Operating Lease Liability
645
638
Federal Income Taxes Payable
–
74
Accrued Expenses
1,227
1,258
Accrued Selling Expense
169
237
Accrued Warranty Costs
173
52
Contract Loss Reserves
423
259
Customer Advance Deposits
285
255
Current Liabilities
4,700
4,950
Other Liabilities
Operating Lease Liability, net of current portion
1,346
1,760
Other Liabilities
1,346
1,760
Total Liabilities
6,046
6,710
Commitments and Contingencies
–
–
Stockholders’ Equity
Common Stock – ($0.001 par, 2,000,000,000 authorized, 6,912,919 and 6,873,938 shares issued and outstanding, respectively)
7
7
Additional Paid in Capital
21,669
21,465
Retained Earnings (Accumulated Deficit)
1,458
(2,664
)
Stockholders’ Equity
23,134
18,808
Total Liabilities and Stockholders’ Equity
$
29,180
$
25,518
The accompanying notes in our Quarterly Report on Form 10Q for the three and nine months ended June 29, 2025 filed with the SEC on August 12, 2025 are an integral part of these financial statements.
Optex Systems Holdings, Inc. Condensed Consolidated Statements of Operations (Unaudited)
(Thousands, except share and per share data)
Three months ended
Nine months ended
June 29, 2025
June 30, 2024
June 29, 2025
June 30, 2024
Revenue
$
11,110
$
9,060
$
30,038
$
24,552
Cost of Sales
7,942
6,179
21,380
17,430
Gross Profit
3,168
2,881
8,658
7,122
General and Administrative Expense
1,257
1,266
3,593
3,599
Operating Income
1,911
1,615
5,065
3,523
Interest Expense
–
17
12
32
Income Before Taxes
1,911
1,598
5,053
3,491
Income Tax Expense, net
401
337
931
737
Net Income
$
1,510
$
1,261
$
4,122
$
2,754
Basic income per share
$
0.22
$
0.19
$
0.60
$
0.41
Weighted Average Common Shares Outstanding – basic
6,884,429
6,799,807
6,856,776
6,744,997
Diluted income per share
$
0.22
$
0.18
$
0.60
$
0.40
Weighted Average Common Shares Outstanding – diluted
6,929,625
6,888,208
6,911,817
6,812,431
The accompanying notes in our Quarterly Report on Form 10Q for the three and nine months ended June 29, 2025 filed with the SEC on August 12, 2025 are an integral part of these financial statements.
ABOUT OPTEX SYSTEMS
Optex, which was founded in 1987, is a Richardson, Texas based ISO 9001:2015 certified concern, which manufactures optical sighting systems and assemblies, primarily for Department of Defense (DOD) applications. Its products are installed on various types of U.S. military land vehicles, such as the Abrams and Bradley fighting vehicles, Light Armored and Armored Security Vehicles, and have been selected for installation on the Stryker family of vehicles. Optex also manufactures and delivers numerous periscope configurations, rifle and surveillance sights, and night vision optical assemblies. Optex delivers its products both directly to the military services and to prime contractors. For additional information, please visit the Company’s website at www.optexsys.com.
Safe Harbor Statement
This press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the products and services described herein. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” and similar expressions.
These forward-looking statements represent our expectations, beliefs, intentions or strategies concerning future events, including, but not limited to, any statements regarding growth strategy; product and development programs; financial performance and financial condition (including revenue, net income, profit margins and working capital); customer demand; orders and backlog; expected timing of contract deliveries to customers and corresponding revenue recognition; increases in the cost of materials and labor; costs remaining to fulfill contracts; contract loss reserves; labor shortages; follow-on orders; supply chain challenges; the continuation of historical trends; the sufficiency of our cash balances for future liquidity and capital resource needs; the expected impact of changes in accounting policies on our results of operations, financial condition or cash flows; anticipated problems and our plans for future operations; and the economy in general or the future of the defense industry.
These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, continued funding of defense programs and military spending, the timing of such funding, general economic and business conditions, including unforeseen weakness in the Company’s markets, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in the U.S. Government’s interpretation of federal procurement rules and regulations, changes in spending due to policy changes in any new federal presidential administration, market acceptance of the Company’s products, shortages in components, production delays due to performance quality issues with outsourced components, inability to fully realize the expected benefits from acquisitions and restructurings or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, changes to export regulations, increases in tax rates, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, unanticipated costs under fixed-price service and system integration engagements, changes in the market for microcap stocks regardless of growth and value and various other factors beyond our control.
You must carefully consider any such statement and should understand that many factors could cause actual results to differ from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. You should carefully evaluate such statements in light of factors described in the Company’s filings with the SEC, especially on Forms 10-K, 10-Q and 8-K. In various filings the Company has identified important factors that could cause actual results to differ from expected or historic results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete list of all potential risks or uncertainties.
Manuscript accepted for publication in Frontiers in Pharmacology, “Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism” details Ketamir-2’s superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025.
MIAMI, FL / ACCESS Newswire / August 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance of a second peer-reviewed manuscript describing its lead oral drug candidate, Ketamir-2, in Frontiers in Pharmacology.
The newly accepted publication reports that Ketamir-2 outperformed ketamine, pregabalin, or gabapentin-depending on the comparator used-in restoring sensory function and reversing pain behaviors across two gold-standard rodent models of neuropathic pain. The findings build on MIRA’s first publication characterizing Ketamir-2’s clean pharmacology and favorable safety profile and align with the Company’s plan to initiate a Phase 2a trial in neuropathic pain by year-end 2025.
Market Opportunity
Neuropathic pain represents a significant and underserved market across North America. Epidemiology suggests approximately 7-10% of the population experiences neuropathic pain; in North America, this equates to approximately 36-51 million people across the U.S., Canada, and Mexico. According to Precedence Research, the global neuropathic pain market is valued at approximately $7.97 billion in 2024 and is projected to reach $16.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.73%. North America accounts for a significant share of this market, representing an estimated $3.7-3.9 billion annually today. The U.S. neuropathic pain market is estimated at $2.79 billion in 2024 and is projected to reach $5.92 billion by 2034, growing at a CAGR of 7.80% over the same period. Growth is expected to be driven by rising prevalence of diabetes, cancer survivorship, and aging-related nerve damage, underscoring the large and expanding commercial potential for novel treatments such as Ketamir-2.
Ketamir-2’s differentiated mechanism, oral bioavailability, and superior performance in gold-standard preclinical models position it as a potential next-generation, non-opioid treatment option in this multi-billion-dollar and rapidly growing market.
Key Findings from the Publication
Chung Model (sciatic nerve ligation in rats)
Male rats: Ketamir-2 restored sensory thresholds toward baseline, while ketamine-tested as the comparator-showed no measurable benefit.
Female rats: Ketamir-2 outperformed both pregabalin and gabapentin, delivering greater and more consistent restoration of normal sensory responses.
Paclitaxel (PTX)-Induced Neuropathy in Mice
Gabapentin was the sole comparator in this chemotherapy-induced neuropathy model. Ketamir-2 produced more complete normalization of pain sensitivity in both male and female cohorts, while gabapentin provided only partial or inconsistent relief.
Efficacy Across Genders and Species Despite differences in baseline pain sensitivity between male and female animals, Ketamir-2 demonstrated clear and significant therapeutic benefit in every cohort tested.
Mechanistic Differentiation
Ketamir-2 is a new molecular entity that selectively binds to the PCP site of the NMDA receptor with low affinity and shows no significant interaction with over 40 other receptor systems, including serotonin, dopamine, and opioid receptors. This combination of selectivity, oral bioavailability, and demonstrated efficacy in gold-standard models suggests the potential for a differentiated, next-generation therapeutic option in neuropathic pain.
“The acceptance of this second peer-reviewed publication is another important milestone for our Ketamir-2 program,” said Erez Aminov, CEO of MIRA. “The data clearly demonstrate superior and more consistent pain relief compared to leading neuropathic pain drugs, within the specific models tested. This provides additional confidence as we advance Ketamir-2 toward Phase 2a clinical evaluation and continue to explore its potential in broader CNS applications.”
“The robust reversal of pain sensitivity observed in these well-validated preclinical models-whether compared to ketamine, pregabalin, or gabapentin-further supports Ketamir-2’s potential as a differentiated, orally administered treatment for neuropathic pain,” added Dr. Itzchak Angel, Chief Scientific Advisor. “Given the limited number of effective oral treatments for this indication, Ketamir-2’s profile is especially compelling.”
Clinical Development Update
Phase 1 Trial Progressing: The ongoing Phase 1 trial of Ketamir-2 in Israel is on schedule, with no safety concerns reported to date and the single ascending dose portion nearing completion.
Phase 2a by Year-End: MIRA plans to submit a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) in Q4 2025 as an advanced development version to its active IND, with the goal of initiating the study in neuropathic pain by year-end.
Potential Beyond Neuropathic Pain: With its clean pharmacology and oral bioavailability, Ketamir-2 is also being explored for potential applications in depression, anxiety, post-traumatic stress disorder (PTSD), and as a topical formulation for localized pain conditions.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
